MANKIND PHARMA
|
|
BOM : 543904     NSE : MANKIND     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : NA |
Oct 07,2024 |
Price(EOD): ₹ 2,558.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 102,495.51 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
MANKIND PHARMA | 1.5% | 3.6% | 45% |
SUN PHARMACEUTICAL INDUSTRIES | -1.1% | 4.4% | 67.3% |
CIPLA | -1.8% | -0.2% | 37.2% |
DR REDDYS LABORATORIES | -2.3% | -1.4% | 21.5% |
ZYDUS LIFESCIENCES | -1.6% | -5.8% | 73.2% |
DIVIS LABORATORIES | -0.8% | 5.4% | 45.7% |
FUNDAMENTAL ANALYSIS OF MANKIND PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF MANKIND PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
51.87
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,976.25 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 10.98
P/B Calculated based on Book Value of Rs 9,339.84 Cr
[Latest Year - Mar2024 - Consolidated Results ] 9.63
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 10,649.60 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
13021% 11828% - |
SHARE PRICE MOMENTUM OF MANKIND PHARMA
MANKIND PHARMA vs SENSEX
DEBT OF MANKIND PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0.1 0.03 |
0.02 0.02 0.14 0.06 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF MANKIND PHARMA
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF MANKIND PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
18.53% 15.34% 16.61% 13.7% |
12.21% 4.12% 7.09% 10.15% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
MANKIND PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | -3% | -0.7% | 51.3% |
S&P BSE 500 | -5.4% | -2.5% | 33.4% |
S&P BSE ALLCAP | -5.4% | -2.6% | 34.2% |
S&P BSE LARGE MIDCAP | -5.4% | -2.4% | 32.2% |
S&P BSE 200 | -5.4% | -2.2% | 32.5% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY PHARMA | -2.3% | -0.9% | 49% |
NIFTY MID SMALL400 | -4.9% | -3.4% | 41.4% |
NIFTY MIDCAP150 | -4.9% | -2.9% | 40.4% |
NIFTY FREE MIDCAP 100 | -5.1% | -3.3% | 41.4% |
NIFTY500 MULTICAP 50:25:25 | -5.2% | -2.8% | 36.7% |
You may also like the below Video Courses
FAQ about MANKIND PHARMA
Is MANKIND PHARMA good for long term investment?
As on Oct 07,2024, the Fundamentals of MANKIND PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of MANKIND PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is MANKIND PHARMA UnderValued or OverValued?
As on Oct 07,2024, MANKIND PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of MANKIND PHARMA ?
As on Oct 07,2024, the Intrinsic Value of MANKIND PHARMA is Rs. 20.47 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 19.50
Fair Value [Median EV / Sales Model] : Rs. 21.45
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of MANKIND PHARMA : Rs. 20.47
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.